Comparing the Efficacy and Safety of Fremanezumab for Chronic Cluster Headache

- Chronic Cluster Headache
- Terminated

Study Title: A Study Comparing the Efficacy and Safety of Fremanezumab (TEV-48125) for the Prevention of Chronic Cluster Headache (CCH)

Teva Identifier: TV48125-CNS-30057 | 2016-003171-21

ClinicalTrials.gov Identifier: NCT02964338

Study Status: Terminated

Trial Condition(s): Chronic Cluster Headache

Interventions: Drug: Fremanezumab | Drug: Placebo

Study Description

Please refer to ClinicalTrials.gov for a description of the trial

Participation criteria and map of study locations

Key Participation Requirements

Gender: Female, Male

Age group: Adult, Older Adult

Age Range: 18 Years to 70 Years

Trial Duration: January 17, 2017 - July 18, 2018

Phase: Phase 3

Plain Language Summary

Study Type

Interventional